Ticker Details
Biogen Inc. Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
IPO Date:	January 3, 1994
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$25.99B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$2.46 | 1.33%
Avg Daily Range (30 D):	$2.52 | 1.37%
Avg Daily Range (90 D):	$2.58 | 1.42%

Institutional Daily Volume
Avg Daily Volume:	2.06M
Avg Daily Volume (30 D):	.79M
Avg Daily Volume (90 D):	1.16M

Trade Size
Avg Trade Size (Sh.):	105
Avg Trade Size (Sh.) (30 D):	36
Avg Trade Size (Sh.) (90 D):	41

Institutional Trades
Total Institutional Trades:	44,803
Avg Institutional Trade:	$6.19M
Avg Institutional Trade (30 D):	$16.24M
Avg Institutional Trade (90 D):	$18.4M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	7

Market Closing Trades
Avg Closing Trade:	$28.49M
Avg Closing Trade (30 D):	$45.01M
Avg Closing Trade (90 D):	$55.5M
Avg Closing Volume:	139.26K

News

Apr 7, 2026 @ 12:54 PM Biogen Taps Alloy Platform To Push Antisense Drug ... Source: Vandana Singh

Apr 6, 2026 @ 5:00 PM Idiopathic Membranous Nephropathy Market is Predic... Source: Delveinsight

Apr 3, 2026 @ 2:35 PM Deal Dispatch: McCormick, Unilever Merge, Sysco Ac... Source: Caroline Ryan

Apr 1, 2026 @ 5:00 PM Systemic Lupus Erythematosus Clinical Trial Pipeli... Source: Delveinsight

Mar 31, 2026 @ 5:27 PM Trump Signals Iran Exit, S&P 500 Heads For Worst M... Source: Piero Cingari

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$8.83	$-.33	$8.83
Diluted EPS	$8.79	$-.35	$8.79
Revenue	$9.89B	$2.28B	$9.89B
Gross Profit	$7.49B	$1.78B	$7.49B
Net Income / Loss	$1.29B	$-48.9M	$1.29B
Operating Income / Loss	$1.56B	$-56M	$1.56B
Cost of Revenue	$2.4B	$495.5M	$2.4B
Net Cash Flow	$633.5M	$-854.3M	$633.5M
PE Ratio	19.68

Splits
Jan 18, 2001	3:1